Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-07-01
2008-12-30
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S200000
Reexamination Certificate
active
07470678
ABSTRACT:
Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described
REFERENCES:
patent: 5306817 (1994-04-01), Thiruvengadam et al.
patent: 5631365 (1997-05-01), Rosenblum et al.
patent: 5633246 (1997-05-01), McKittrick et al.
patent: 5661145 (1997-08-01), Davis
patent: 5739321 (1998-04-01), Wu et al.
patent: 5744467 (1998-04-01), McKittrick et al.
patent: 5756470 (1998-05-01), Yumibe et al.
patent: 5767115 (1998-06-01), Rosenblum et al.
patent: 5846966 (1998-12-01), Rosenblum et al.
patent: 5886171 (1999-03-01), Wu et al.
patent: 5919672 (1999-07-01), Homann et al.
patent: RE37721 (2002-05-01), Rosenblum et al.
patent: 7235543 (2007-06-01), Burnett et al.
patent: 2002/0137690 (2002-09-01), Ghosal et al.
patent: 2003/0119428 (2003-06-01), Davis et al.
patent: 2003/0119757 (2003-06-01), Davis
patent: 2004/0018060 (2003-06-01), Kaezek et al.
patent: 2004/0018061 (2004-01-01), Jansson
patent: 2004/0254369 (2004-12-01), Patel
patent: 2005/0096307 (2005-05-01), Graziano
patent: 2005/0267049 (2005-12-01), Goulet et al.
patent: 2006/0046996 (2006-03-01), Aoki et al.
patent: 2006/0069080 (2006-03-01), Veltri
patent: 2007/0049748 (2007-03-01), Uppala et al.
patent: 2007/0078098 (2007-04-01), DEVita et al.
patent: 2007/0129540 (2007-06-01), Framroze et al.
patent: 2007/0142304 (2007-06-01), Alenfalk et al.
patent: 2007/0155674 (2007-07-01), Burnett et al.
patent: 2007/0155675 (2007-07-01), Burnett et al.
patent: 2008/0064676 (2008-03-01), Alenfalk et al.
patent: 524595 (1993-01-01), None
patent: 1413331 (2001-09-01), None
patent: 0792264 (2002-02-01), None
patent: 1362855 (2003-11-01), None
patent: 9302048 (1993-02-01), None
patent: 9414433 (1994-07-01), None
patent: 9417038 (1994-08-01), None
patent: 95/01961 (1995-01-01), None
patent: 9508532 (1995-03-01), None
patent: 9526334 (1995-10-01), None
patent: 9535277 (1995-12-01), None
patent: 9609827 (1996-04-01), None
patent: 9616037 (1996-05-01), None
patent: 9619450 (1996-06-01), None
patent: 9716424 (1997-05-01), None
patent: 9716455 (1997-05-01), None
patent: 9745406 (1997-12-01), None
patent: 0020623 (2000-04-01), None
patent: 0034240 (2000-06-01), None
patent: 0038725 (2000-07-01), None
patent: 0060107 (2000-10-01), None
patent: 0063703 (2000-10-01), None
patent: 0218432 (2002-03-01), None
patent: 0250027 (2002-06-01), None
patent: 0250060 (2002-06-01), None
patent: 0250068 (2002-06-01), None
patent: 0250090 (2002-06-01), None
patent: 02058685 (2002-08-01), None
patent: 02058696 (2002-08-01), None
patent: 02058732 (2002-08-01), None
patent: 02058733 (2002-08-01), None
patent: 02066464 (2002-08-01), None
patent: 020508734 (2002-08-01), None
patent: 02072104 (2002-09-01), None
patent: 02079174 (2002-10-01), None
patent: 02096415 (2002-12-01), None
patent: 03026643 (2003-04-01), None
patent: 03026644 (2003-04-01), None
patent: 03088962 (2003-10-01), None
patent: 2004000803 (2003-12-01), None
patent: 2004000804 (2003-12-01), None
patent: 2004000805 (2003-12-01), None
patent: 2004005247 (2004-01-01), None
patent: 2004010948 (2004-02-01), None
patent: 2004010993 (2004-02-01), None
patent: 2004014947 (2004-02-01), None
patent: 0403457 (2004-05-01), None
patent: 04043456 (2004-05-01), None
patent: 2004081002 (2004-09-01), None
patent: 04099132 (2004-11-01), None
patent: 04107958 (2004-12-01), None
patent: 05000353 (2005-01-01), None
patent: 2005021495 (2005-03-01), None
patent: WO 2005021497 (2005-03-01), None
patent: 2005033100 (2005-04-01), None
patent: 05042692 (2005-05-01), None
patent: 2005044256 (2005-05-01), None
patent: 2005047248 (2005-05-01), None
patent: 2005049592 (2005-06-01), None
patent: 2005058316 (2005-06-01), None
patent: 2005061451 (2005-07-01), None
patent: 2005061452 (2005-07-01), None
patent: 2005062824 (2005-07-01), None
patent: 2005062897 (2005-07-01), None
patent: 2005066120 (2005-07-01), None
patent: 2005067903 (2005-07-01), None
patent: 2005069900 (2005-08-01), None
patent: 2005113495 (2005-12-01), None
patent: 2005113496 (2005-12-01), None
patent: 2006017257 (2006-02-01), None
patent: 2006060808 (2006-06-01), None
patent: 2006068990 (2006-06-01), None
patent: 2006072957 (2006-07-01), None
patent: 2006086562 (2006-08-01), None
patent: 2006102674 (2006-09-01), None
patent: 2006107936 (2006-10-01), None
patent: 2006116499 (2006-11-01), None
patent: 2006121861 (2006-11-01), None
patent: 2006122186 (2006-11-01), None
patent: 2006122216 (2006-11-01), None
patent: 2006124713 (2006-11-01), None
patent: 2006127893 (2006-11-01), None
patent: 2006134604 (2006-12-01), None
patent: 2006137080 (2006-12-01), None
patent: 2006137782 (2006-12-01), None
patent: 2006137792 (2006-12-01), None
patent: 2006137793 (2006-12-01), None
patent: 2006137794 (2006-12-01), None
patent: 2006137795 (2006-12-01), None
patent: 2006137796 (2006-12-01), None
patent: 2006137797 (2006-12-01), None
patent: 2006138163 (2006-12-01), None
patent: 2007003365 (2007-01-01), None
patent: 2007008529 (2007-01-01), None
patent: 2007008541 (2007-01-01), None
patent: 2007015161 (2007-02-01), None
patent: 2007016643 (2007-02-01), None
patent: 2007017705 (2007-02-01), None
patent: 2007030721 (2007-03-01), None
patent: 2007058335 (2007-05-01), None
patent: 2007059871 (2007-05-01), None
patent: 2007072088 (2007-06-01), None
patent: 2007075702 (2007-07-01), None
patent: 02058731 (2008-08-01), None
Clader et al., “2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus,” J. Med Chem (1996) 39:3684-3693.
McKittrick et al., Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors, Bioorganic & Medicinal Chemistry Letters (1996) 6(16):1947-1950.
Burnett et al., “2-Azetidinones as Inhibitors of Cholesterol Absorption,” J. Med Chem (1994) 12:1733-1736.
Castaner et al., “Ezetimibe,” Drugs of the Future (2000) 25(7):679-685.
Vaccaro et al., “Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: Enhanced potency by modification of the sugar,” Bioorganic & Medicinal Chemistry Letters (1998) 8:313-318.
Fu et al., “Process for preparing Ezetimibe intermediate by an acid enhanced chemo- and enantioselective CBS catalyzed ketone reduction,” Tetrahedron Letters (2003) 44:801-804.
Kirkup et al., “(—)-SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor,” Bioorganic & Medicinal Chemistry Letters (1996) 6(17):2069-2072.
Vaccaro et al., “Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors,” Bioorganic & Medicinal Chemistry Letters (1998) 8:319-322.
Rosenblum et al., “Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 - hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.,” J. Med Chem (1998) 41:973-980.
Wu et al., “A Novel One-Step Diastereo- and Enantioselective Formation of trans-Azetidinones and Its Application to the Total Synthesis of Cholesterol Absorption Inhibitors,” J. Org. Chem (1999) 64:3714-3718.
McKittrick et al., “Synthesis of C3 heteroatom-substituted azetidinones that display potent cholesterol absorption inhibitory activity,” J. Med. Chem. (1998) 41(5):752-759.
Kvaerno et al., “Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption,” J Med Chem (2005) 48(19):6035-6053.
Burnett “Beta-lactam cholesterol absorption inhibitors,” Curr Med Chem (2004) 11:1873-1887.
Seedorf et al., “Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages,” Biochem Biophys Research Commun (2004) 320(4):1337-1341.
Kvaerno et al., “An i
Dahlstrom Mikael Ulf Johan
Lemurell Malin Anita
Lindqvist Ann-Margret
Nordberg Mats Peter
Skjaret Tore
AstraZeneca AB
Berch Mark L
Pepper Hamilton LLP
LandOfFree
Diphenylazetidinone derivatives for treating disorders of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diphenylazetidinone derivatives for treating disorders of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diphenylazetidinone derivatives for treating disorders of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4033691